In CAP for patients with significant comorbidities, you want a single agent that can cover both typical bacteria and atypical pathogens. Levofloxacin has broad activity against Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Moraxella, and atypicals such as Mycoplasma, Chlamydophila, and Legionella, so it provides comprehensive coverage without needing a second drug. Amoxicillin alone misses atypicals, and amoxicillin-clavulanate plus a macrolide involves two agents; doxycycline alone may be less reliable against resistant pneumococcus and isn’t the preferred sole therapy in more ill patients.

Hib vaccine prevents meningitis caused by Haemophilus influenzae type b by inducing antibodies to the type b capsule, stopping invasive Hib disease before it can cause meningitis. Because Hib used to be a common cause of meningitis in young children, the vaccine is included in routine immunization schedules for appropriate populations, starting in infancy and continuing with follow-up doses. It remains recommended for those groups at risk, not only adults and not as something that has been discontinued. It also does not replace pneumococcal vaccination, since those vaccines protect against different organisms and are given as part of separate immunization plans.

Protease inhibitors block the HIV protease enzyme, preventing cleavage of the Gag-Pol polyprotein and producing immature, noninfectious virus particles. Lopinavir is a protease inhibitor, typically given with ritonavir to boost its levels, making it a standard option in combination antiretroviral therapy. Efavirenz is an NNRTI, which inhibits reverse transcriptase to stop conversion of viral RNA into DNA. Dolutegravir is an integrase strand transfer inhibitor, preventing integration of viral DNA into the host genome. Enfuvirtide is a fusion inhibitor that blocks entry by binding gp41 on the viral envelope.

Campylobacter jejuni infection commonly precedes Guillain-Barré syndrome, an autoimmune attack on the peripheral nerves triggered by molecular mimicry between the bacteria’s components and neuronal gangliosides. The immune response, aimed at the infection, cross-reacts with nerve components, causing demyelination or axonal damage that leads to progressive, symmetric weakness with absent reflexes. Clinically, patients often have an ascending pattern of weakness and may develop facial weakness or autonomic instability. Lumbar puncture typically shows high protein with normal cell count (albuminocytologic dissociation), and nerve studies reveal demyelination or axonal damage depending on the variant. Treatment with IVIG or plasmapheresis improves outcomes, and many patients recover, though some may have residual deficits. The other conditions listed are not classically linked as post-infectious complications of Campylobacter jejuni: Bell palsy is facial nerve palsy from various causes; multiple sclerosis involves central nervous system demyelination; myasthenia gravis affects the neuromuscular junction.